4.6 Article

Autoantibodies Specific for the Phospholipase A2 Receptor in Recurrent and De Novo Membranous Nephropathy

Journal

AMERICAN JOURNAL OF TRANSPLANTATION
Volume 11, Issue 10, Pages 2144-2152

Publisher

WILEY
DOI: 10.1111/j.1600-6143.2011.03643.x

Keywords

De novo; membranous nephropathy; PLA(2)R1; recurrent

Funding

  1. Agence de la Biomedecine
  2. Agence Nationale pour la Recherche [ANR-07-Physio-016-01]
  3. European Community [HEALTH-F2-2007-201590]
  4. Fondation pour la Recherche Medicale
  5. Association pour l'Utilisation du Rein Artificiel (AURA)
  6. Assistance Publique-Hopitaux de Paris

Ask authors/readers for more resources

Recent findings in idiopathic membranous nephropathy (MN) suggest that in most patients, the disease is because of anti-phospholipase A(2) receptor (PLA(2)R1) autoantibodies. Our aim was to analyze the prevalence and significance of anti-PLA(2)R1 antibodies in recurrent and de novo MN after transplantation. We assessed circulating PLA(2)R1 autoantibodies by a direct immunofluorescence assay based on human embryonic kidney cells transfected with a PLA(2)R1 cDNA, and the presence of PLA(2)R1 antigen in immune deposits. We showed that PLA(2)R1 was involved in 5 of 10 patients with recurrent MN, but in none of the 9 patients with de novo MN. We also showed a marked heterogeneity in the kinetics and titers of anti-PLA(2)R1, which may relate to different pathogenic potential. We provide evidence that some patients with PLA(2)R1-related idiopathic MN and anti-PLA(2)R1 antibodies at the time of transplantation will not develop recurrence. Because PLA(2)R1 autoantibody was not always associated with recurrence, its predictive value should be carefully analyzed in prospective studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available